Maxwell Kirkby
CIK: 0002060862
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
GYRE
GYRE THERAPEUTICS, INC.
Director
Discretionary Trading P&L
Holdings
About Kirkby Maxwell
Kirkby Maxwell (SEC CIK 0002060862) files insider reports with the SEC as Director of GYRE THERAPEUTICS, INC. (GYRE).
Signal8 holds 2 ownership filings by Kirkby Maxwell (1 Form 3, 1 Form 4), filed on Aug 4, 2026. Those filings report 1 transaction, the latest on Aug 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kirkby Maxwell's filings is in SAN DIEGO, CA.
Recent filings by Kirkby Maxwell
- Aug 3, 2026: Grant or award of GYRE derivative securities (Form 4, code A).
Other insiders filing for GYRE THERAPEUTICS, INC. (GYRE)
- Weston Claire, Director
- Ye Weiguo, Chief Operating Officer
- Bergmann Joshua Benjamin, GC and Corporate Secretary
- Luo Ying, Chief Executive Officer
- Zhang Ping, Director
- Wang Jialiang (NMN), EVP, General Manager